BIONTECH SE SPON. ADRS 1
Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET
Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 28th, 2024 | 07:30 CET
PRICE SURGE or SELL-OFF: Buy BioNTech? Is Evotec on the verge of a slump? BioNxt Solutions share on the brink of a breakout?
Price opportunity with BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a quick 50% gain could be possible. In any case, things are going well operationally. The Company is developing next-generation drug delivery systems. The Evotec share is not for the faint-hearted. After the price jump following the takeover offer, a sharp drop followed. Analysts see the fair value of the biotech company well below the current price. Will takeover speculation continue? The BioNTech share has avoided slipping below EUR 100. Analysts view the data on the breast cancer candidate positively and recommend buying.
Read
Commented by André Will-Laudien on November 27th, 2024 | 07:00 CET
Biotech in focus! The 2025 blockbusters: Pfizer, BioNTech, Nyxoah, Valneva or Evotec - Who will take off?
The Q3 figures have now been processed. In the shadow of the tech giants on the Nasdaq, biotech stocks are currently being neglected. However, it is important to note that as pressure on the international economies increases, so does the likelihood of interest rate cuts by the central banks. Many investors have been underweight in biotech for quarters, prioritizing other sectors. All of this could be reversed in 2025. An early positioning with the most important protagonists seems promising. We are picking the best opportunities for you from the "Advent calendar."
Read
Commented by Juliane Zielonka on November 21st, 2024 | 07:15 CET
Bayer, BioNxt Solutions, BioNTech – Patents and acquisitions for market penetration
Three companies in the pharmaceutical industry are pursuing different strategies to strengthen their market position: Bayer is making targeted investments in the Japanese heart medication market and acquiring the rights to a promising active ingredient for treating heart muscle diseases for up to EUR 560 million. BioNxt Solutions is developing an innovative form of medication delivery for drugs to treat the incurable disease of multiple sclerosis - with an absolute focus on patients. The biotech company is thus securing patent protection in key international markets. BioNTech, in turn, is massively expanding into the Asian oncology market with the USD 800 million acquisition of the Chinese company Biotheus. All three companies are expanding their positions in lucrative future markets. Which strategy will be successful?
Read
Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET
Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma
BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?
Read
Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET
The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus
The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.
Read
Commented by Fabian Lorenz on November 14th, 2024 | 07:00 CET
SHARE PRICES EXPLODE as biotech stocks rise! BioNTech, Evotec, Nyxoah
Is Evotec about to make a quick turnaround? A financial investor is positioning itself for a potential takeover, and the stock surged significantly in the last days. Does this mean that the disappointment over the quarterly figures has been forgotten? Could Nyxoah's stock be the next to skyrocket? The chances of this are good. The medtech company expects FDA approval for the first quarter of 2025 and aims to roll out its main product across the US market next year. Analysts see billion-dollar potential, rapidly increasing revenues, and a favourable P/E ratio. BioNTech shares are also benefiting from a rating upgrade by renowned analysts. The target price has been raised significantly. Could this help the German biotech leader break out of its recent consolidation phase?
Read
Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET
Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors
Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?
Read
Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET
US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?
With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.
Read